Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2025)

Monte Rosa Therapeutics' EBT Margin history spans 2 years, with the latest figure at 1656.81% for Q4 2025.

  • For Q4 2025, EBT Margin fell 176403.0% year-over-year to 1656.81%; the TTM value through Dec 2025 reached 32.12%, down 474.0%, while the annual FY2025 figure was 32.12%, 474.0% down from the prior year.
  • EBT Margin reached 1656.81% in Q4 2025 per GLUE's latest filing, down from 236.98% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 107.22% in Q4 2024 to a low of 2996.71% in Q1 2024.